BioSpace News Archive

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.

Ocugen, Inc. today announced that the FDA has granted Orphan Drug Designation for its OCU410ST (AAV5- hRORA), an adeno-associated virus serotype 5 capsid protein containing gene construct encoding human retinoic acid receptor-related orphan receptor alpha, for the “treatment of ABCA4-associated retinopathies” including Stargardt, Retinitis Pigmentosa 19 (RP19), and Cone-rod dystrophy 3 (CORD3) diseases.

Intellia Therapeutics, Inc. will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.

Organogenesis Holdings Inc. today announced that its Board of Directors has elected President and Chief Executive Officer Gary S. Gillheeney, Sr., as Chair of the Board, effective immediately.

Ociperlimab is one of the two TIGIT inhibitors that has progressed the farthest in clinical trials and based on data from clinical and preclinical trial, is anticipated to gain regulatory approval in the next few years.

OncoSec Medical Incorporated today announced the receipt of $3.49 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA).

Trevi Therapeutics, Inc. today announced senior management will attend and present at the following May 2023 investor events.

HCW Biologics Inc. entered into a $26.25 million development line of credit agreement on April 21, 2023.

Zura Bio Limited today announced the license from Eli Lilly and Company (“Lilly”) of tibulizumab, a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist.

InspireMD, Inc. announced it will report first quarter 2023 financial results on Tuesday, May 9th, 2023, before the financial markets open.